854300-39-3

Upstream product

• 261380-28-3 (R)-2-((tert-butoxycarbonyl)amino)-3-(2-cyanophenyl)propanoic acid 

Downstream Products

• 854300-53-1 [1-(4-hydroxy-2,6-dimethylbenzyl)-2(S)-(3-oxo-4(R)-phenylacetylamino-1,2,4,5-tetrahydrobenzo[c]azepin-2-yl)-ethyl]carbamic acid 9H-fluoren-9-ylmethyl ester 
• 854300-55-3 [1-(4-hydroxy-2,6-dimethylbenzyl)-2(R)-(3-oxo-4(R)-phenylacetylamino-1,2,4,5-tetrahydrobenzo[c]azepin-2-yl)-ethyl]carbamic acid 9H-fluoren 9-ylmethyl ester 
• 854300-47-3 3-[4(R)-(Boc-amino)-1,2,4,5-tetrahydro-2-benzazepine-3-one-2-yl]-2(R)-Fmoc-amino-1-(2,6-dimethyl-4-hydroxyphenyl)propane 
• 854300-45-1 3-[4(R)-(Boc-amino)-1,2,4,5-tetrahydro-2-benzazepine-3-one-2-yl]-2(S)-Fmoc-amino-1-(2,6-dimethyl-4-hydroxyphenyl)propane 

Relevant academic research and scientific papers

PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.

A new structural motif for μ-opioid antagonists

On the basis of the structural features of the Dmt-Tic pharmacophore, a new motif leading to a fairly potent μ-opioid antagonist is described. This motif contains the 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-one skeleton as a substitute for the Tic resi